MRV Research

BeiGene Doses First Patient in China With BGB-283 for Solid Tumors – See more at:

BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient has been dosed with BGB-283 in a Phase I clinical trial in China, a novel RAF dimer inhibitor for the treatment of solid tumors harboring B-RAF mutations and other aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway. The study is being conducted across multiple centers in China.

Read More

Pediatric melanoma: Occurrence is rare, yet most common type of skin cancer in children

MRV Research, Of Interest

It is estimated that there are approximately 400 new cases of melanomas diagnosed annually in the U.S. among those aged younger than 19 years. Melanoma is the most common type of skin cancer that occurs in children, according to St. Jude Children’s Research Hospital, as approximately 7% of all cancers diagnosed in children aged between 15 years and 19 years are melanomas. On a brighter note, the majority of melanomas are diagnosed early on and are highly curable.

Read More
MRV News
Melanoma News
Archive
Menu